Tiago Girao Sells 10,000 Shares of Immunovant (NASDAQ:IMVT) Stock

Posted by George Bondi on Jun 26th, 2026

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) CFO Tiago Girao sold 10,000 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $38.46, for a total value of $384,600.00. Following the transaction, the chief financial officer directly owned 247,596 shares of the company’s stock, valued at approximately $9,522,542.16. This represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Tiago Girao also recently made the following trade(s):

On Thursday, April 23rd, Tiago Girao sold 25,760 shares of Immunovant stock. The shares were sold at an average price of $29.62, for a total value of $763,011.20.

Immunovant Stock Performance

Shares of IMVT stock traded up $0.61 on Friday, hitting $38.85. The company had a trading volume of 3,718,031 shares, compared to its average volume of 1,598,367. The firm has a market cap of $7.98 billion, a P/E ratio of -13.97 and a beta of 0.76. The stock’s 50-day moving average is $31.24 and its two-hundred day moving average is $27.69. Immunovant, Inc. has a twelve month low of $14.32 and a twelve month high of $39.28.

Immunovant (NASDAQ:IMVT – Get Free Report) last issued its quarterly earnings data on Wednesday, May 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.13). During the same period in the prior year, the company posted ($0.64) earnings per share. Equities research analysts predict that Immunovant, Inc. will post -2.65 EPS for the current year.

Analysts Set New Price Targets

IMVT has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Immunovant in a research report on Wednesday, April 8th. Truist Financial increased their price objective on shares of Immunovant from $23.00 to $30.00 and gave the stock a “hold” rating in a research report on Friday, May 22nd. Bank of America boosted their target price on shares of Immunovant from $32.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Sanford C. Bernstein initiated coverage on shares of Immunovant in a research report on Friday, March 20th. They set a “market perform” rating and a $28.00 price target on the stock. Finally, The Goldman Sachs Group upped their price target on shares of Immunovant from $29.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Immunovant presently has a consensus rating of “Hold” and a consensus price target of $37.33.

Read Our Latest Stock Analysis on IMVT

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Empowered Funds LLC boosted its stake in Immunovant by 2.7% during the first quarter. Empowered Funds LLC now owns 14,556 shares of the company’s stock worth $362,000 after acquiring an additional 381 shares in the last quarter. Wellington Management Group LLP grew its holdings in Immunovant by 2.7% in the fourth quarter. Wellington Management Group LLP now owns 28,847 shares of the company’s stock worth $733,000 after purchasing an additional 755 shares during the period. Royal Bank of Canada increased its stake in Immunovant by 20.7% in the fourth quarter. Royal Bank of Canada now owns 4,549 shares of the company’s stock valued at $116,000 after purchasing an additional 780 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Immunovant by 2.6% in the second quarter. The Manufacturers Life Insurance Company now owns 36,124 shares of the company’s stock valued at $578,000 after purchasing an additional 900 shares in the last quarter. Finally, Banque Pictet & Cie SA raised its holdings in shares of Immunovant by 0.9% during the fourth quarter. Banque Pictet & Cie SA now owns 114,881 shares of the company’s stock valued at $2,920,000 after purchasing an additional 993 shares during the period. Institutional investors and hedge funds own 47.08% of the company’s stock.

About Immunovant

(Get Free Report)

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.